GT Biopharma Inc. (GTBP)
NASDAQ
7.16
-0.33 (-4.41%)
Closed
Sep 18, 2026
Day's Range
7.117.52
52 wk Range
0.222011.98
Financial Statements - GTBP - GT Biopharma Inc.
Revenue
0
Net Income
-28.35M▼ 115.4%
EBITDA
-730.00K▲ 94.8%
Free Cash Flow
-12.91M▼ 0.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -12.42M | -14.36M | -13.57M | -21.25M | -57.51M | -6.76M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -15.92M | 800K | 5.41M | 89K | 182K | -18.21M |
| Pre Tax Income | -28.35M | -13.16M | -7.59M | -20.88M | -58.01M | -28.29M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -28.35M | -13.16M | -7.59M | -20.88M | -58.01M | -28.29M |
| EPS Basic | -6.68 | -6.94 | -5.5836 | -19.4634 | -61.8 | -193.5 |
| EPS Diluted | -6.68 | -6.94 | -5.5836 | -19.4634 | -61.8 | -193.5 |
| Basic Shares Outstanding | 5.51M | 1.89M | 1.36M | 1.07M | 938.52K | 146.17K |
| Diluted Shares Outstanding | 5.51M | 1.89M | 1.36M | 1.07M | 938.52K | 146.17K |
| Ebit | -28.22M | -13.16M | -7.38M | -20.87M | -57.29M | -24.97M |
| Ebitda | -730K | -13.96M | -12.77M | -20.96M | -57.47M | -19.36M |
| Net Income Continuous Operations | -28.35M | -13.16M | -7.59M | -20.88M | -58.01M | -28.29M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | 5.77M | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
